根除幽门螺杆菌：标准四联疗法与优化四联疗法的前瞻性比较随机试验

IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Future Science OA Pub Date : 2024-01-01 DOI:10.2144/fsoa-2023-0316

Salma Souissi, Cyrine Makni, Basma Chaieb, Amine Jarraya, Nadia Toulgui, L. Jmal, Mouna Mlika, Chadlia Fendri, Mohamed Bouchoucha, R. Razgallah, Leila Belhadj Ammar, O. Bousnina, Fawzi Mezni, Awatef Jmal, Lamia Kallel

{"title":"根除幽门螺杆菌：标准四联疗法与优化四联疗法的前瞻性比较随机试验","authors":"Salma Souissi, Cyrine Makni, Basma Chaieb, Amine Jarraya, Nadia Toulgui, L. Jmal, Mouna Mlika, Chadlia Fendri, Mohamed Bouchoucha, R. Razgallah, Leila Belhadj Ammar, O. Bousnina, Fawzi Mezni, Awatef Jmal, Lamia Kallel","doi":"10.2144/fsoa-2023-0316","DOIUrl":null,"url":null,"abstract":"The treatment of Helicobacter pylori infection remains a challenge. None of the proposed treatment regimens has resulted in a 100% eradication rate. The aim of our study was to compare the rate of H. pylori eradication after standard or dose-optimized amoxicillin quadruple therapy. We conducted a prospective comparative study collating patients naive to any anti- H. pylori treatment and with chronic H. pylori infection documented by histological examination. Patients were randomly assigned to either standard quadruple therapy or optimized quadruple therapy. Eradication control was performed by urea breath test. Eighty-eight eligible patients were included with 44 in each group.There was no significant difference between the eradication rates of Qo-14 and Qs-14 neither in ITT (84 vs 70.4%; p = 0.127) nor in PP (82.1 vs 77.7%; p = 0.473). Compliance and tolerance appeared similar in each group.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Eradication of Helicobacter pylori: a prospective comparative randomized trial of standard versus optimized quadruple therapy\",\"authors\":\"Salma Souissi, Cyrine Makni, Basma Chaieb, Amine Jarraya, Nadia Toulgui, L. Jmal, Mouna Mlika, Chadlia Fendri, Mohamed Bouchoucha, R. Razgallah, Leila Belhadj Ammar, O. Bousnina, Fawzi Mezni, Awatef Jmal, Lamia Kallel\",\"doi\":\"10.2144/fsoa-2023-0316\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The treatment of Helicobacter pylori infection remains a challenge. None of the proposed treatment regimens has resulted in a 100% eradication rate. The aim of our study was to compare the rate of H. pylori eradication after standard or dose-optimized amoxicillin quadruple therapy. We conducted a prospective comparative study collating patients naive to any anti- H. pylori treatment and with chronic H. pylori infection documented by histological examination. Patients were randomly assigned to either standard quadruple therapy or optimized quadruple therapy. Eradication control was performed by urea breath test. Eighty-eight eligible patients were included with 44 in each group.There was no significant difference between the eradication rates of Qo-14 and Qs-14 neither in ITT (84 vs 70.4%; p = 0.127) nor in PP (82.1 vs 77.7%; p = 0.473). Compliance and tolerance appeared similar in each group.\",\"PeriodicalId\":12568,\"journal\":{\"name\":\"Future Science OA\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Science OA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2144/fsoa-2023-0316\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2144/fsoa-2023-0316","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

幽门螺旋杆菌感染的治疗仍然是一项挑战。目前所提出的治疗方案中还没有一种能达到 100% 的根除率。我们的研究旨在比较标准或剂量优化阿莫西林四联疗法的幽门螺杆菌根除率。我们进行了一项前瞻性比较研究，研究对象是未接受过任何幽门螺杆菌抗生素治疗的患者，以及经组织学检查证实患有慢性幽门螺杆菌感染的患者。患者被随机分配接受标准四联疗法或优化四联疗法。根除控制通过尿素呼气试验进行。在 ITT（84 vs 70.4%；P = 0.127）和 PP（82.1 vs 77.7%；P = 0.473）中，Qo-14 和 Qs-14 的根除率均无显著差异。各组的依从性和耐受性相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Eradication of Helicobacter pylori: a prospective comparative randomized trial of standard versus optimized quadruple therapy

The treatment of Helicobacter pylori infection remains a challenge. None of the proposed treatment regimens has resulted in a 100% eradication rate. The aim of our study was to compare the rate of H. pylori eradication after standard or dose-optimized amoxicillin quadruple therapy. We conducted a prospective comparative study collating patients naive to any anti- H. pylori treatment and with chronic H. pylori infection documented by histological examination. Patients were randomly assigned to either standard quadruple therapy or optimized quadruple therapy. Eradication control was performed by urea breath test. Eighty-eight eligible patients were included with 44 in each group.There was no significant difference between the eradication rates of Qo-14 and Qs-14 neither in ITT (84 vs 70.4%; p = 0.127) nor in PP (82.1 vs 77.7%; p = 0.473). Compliance and tolerance appeared similar in each group.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

5.00

自引率

4.00%

发文量

审稿时长

13 weeks

期刊介绍： Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries